Flood of comments threatens to delay EMA data disclosure policy

This article was originally published in SRA

13 Nov 2013
News

Ian Schofield @ScripIanS ian.schofield@informa.com

Executive Summary

The huge number of comments – more than 1,000 – received during the public consultation on the European Medicines Agency's proposed policy on clinical trial data disclosure means that finalising the policy may take longer than expected, and that it may well not come into effect on schedule next year¹.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS117609

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS117609

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Flood of comments threatens to delay EMA data disclosure policy

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert